SC 410Alternative Names: SC410
Latest Information Update: 22 Jan 2016
At a glance
- Originator Sancilio & Company
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Non-alcoholic fatty liver disease
Most Recent Events
- 22 Jan 2016 Sancilio & Company plans to submit an IND application with the US FDA for Non-alcoholic fatty liver disease in late 2016 (Sancilio form S-1; December 2015)
- 01 Dec 2014 Preclinical trials in Non-alcoholic fatty liver disease in USA (unspecified route)